Target intelligence / Profile preview

D-alanyl-D-alanine terminus of peptidoglycan pentapeptide (D-Ala-D-Ala)

Target
D-Ala-D-Ala
Molecular classification
Bacterial cell wall component, Peptidoglycan precursor, Dipeptide
01

Overview

The D-alanyl-D-alanine (D-Ala-D-Ala) terminus is a critical structural motif found at the end of the peptidoglycan pentapeptide chain in Gram-positive bacteria [1]. This terminus serves as the essential substrate for transpeptidase enzymes, also known as penicillin-binding proteins (PBPs), which facilitate the cross-linking of peptidoglycan layers to provide mechanical strength and osmotic stability to the bacterial cell wall [2]. It is the primary molecular target for glycopeptide antibiotics like vancomycin, which bind to the terminus with high affinity and sterically hinder the enzymes responsible for cell wall synthesis [1,3]. Because this specific D-amino acid configuration is unique to bacteria and absent in eukaryotic cells, it provides a high degree of selective toxicity for antimicrobial therapy [2]. However, bacterial resistance can emerge through the enzymatic modification of this terminus to D-alanyl-D-lactate or D-alanyl-D-serine, which drastically reduces the binding affinity of glycopeptides and renders the drugs ineffective [1,2].

Other names
D-alanyl-D-alaninePeptidoglycan pentapeptide terminusC-terminal D-Ala-D-AlaBacterial cell wall precursor terminusD-Ala-D-Ala dipeptide
02

Mechanism of action

Glycopeptide antibiotics bind to the D-Ala-D-Ala terminus of the peptidoglycan precursor via five hydrogen bonds, sterically inhibiting the transglycosylation and transpeptidation reactions required for cell wall assembly [1,2].

03

Biological functions

Cell wall synthesisPeptidoglycan cross-linkingBacterial structural integritySubstrate for transpeptidation
04

Disease associations

Bacterial infectionGram-positive bacterial infectionSepsisEndocarditis
05

Safety considerations

Development of antibiotic resistance (e.g., VRE, VRSA) [1]Drug-induced nephrotoxicity [1]Drug-induced ototoxicity [1]Red man syndrome (infusion-related reaction) [3]
06

Interacting drugs

Vancomycin

4 more in the full profile.

07

Biomarkers

VanA genotypeVanB genotypeD-Ala-D-Lac substitutionD-Ala-D-Ser substitution

Beyond the preview

Go deeper on D-alanyl-D-alanine terminus of peptidoglycan pentapeptide (D-Ala-D-Ala).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on D-alanyl-D-alanine terminus of peptidoglycan pentapeptide (D-Ala-D-Ala).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call